Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06135571
Other study ID # NCC4280
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 1, 2023
Est. completion date September 1, 2026

Study information

Verified date November 2023
Source Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Contact Qian Liu, Dr.
Phone 13601008906
Email fcwpumch@163.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this observational study is to learn about the the pattern of metastasis of the No.253 lymph node in colorectal cancer. The main questions it aims to answer are: 1. What are the risk factors for metastasis to the No.253 lymph node? 2.What is the prognosis for patients with metastasis to the No.253 lymph node? Patients with descending colon cancer, sigmoid colon cancer, and rectal cancer who undergo curative surgery with dissection of the No.253 lymph node are included in this study


Description:

The No. 253 lymph node (also named as apical lymph node of inferior mesenteric artery), as the third station in the inferior mesenteric artery lymphatic system, plays a vital role in the lymphatic circulation of the descending colon, sigmoid colon, and rectum. They serve as the last barrier for tumor metastasis from regional to distant sites. The definition of the range of the No.253 lymph node primarily follows the Japanese Colorectal Cancer Treatment Guidelines: the medial boundary is the segment from the root of the inferior mesenteric artery to the origin of the left colic artery, the caudal boundary is from the origin of the left colic artery to the intersection with the inferior mesenteric vein, the lateral boundary is the outer margin of the inferior mesenteric vein, and the cranial boundary is from the horizontal section of the duodenum to the beginning of the jejunum. However, the pattern of metastasis of the No.253 lymph node in colorectal cancer remains unclear, with most studies being retrospective and showing significant differences in results. Therefore, the investigator plans to be the first internationally to carry out this retrospective, registry-based study to determine the metastasis pattern to the No. 253 lymph node in colorectal cancer. This will provide definitive clinical evidence for D3 lymph node dissection in colorectal surgery.


Recruitment information / eligibility

Status Recruiting
Enrollment 3000
Est. completion date September 1, 2026
Est. primary completion date September 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Age: 18-75 years; 2. Underwent laparoscopic left hemicolectomy, sigmoid colectomy, or rectal cancer radical surgery. 3. Postoperative pathology confirmed as adenocarcinoma. 4. No evidence of distant metastasis. Exclusion Criteria: 1. Previous history of malignant colorectal tumors. 2. Patients who have undergone multiple abdominal-pelvic surgeries. 3. Patients undergoing emergency surgery due to complications such as intestinal obstruction, intestinal perforation, or intestinal bleeding. 4. Surgery did not achieve R0 resection. 5. Patients with concurrent other malignant tumors or multiple primary colorectal cancers. 6. Patients unwilling to sign an informed consent or follow the study protocol for follow-up.

Study Design


Intervention

Procedure:
Laparoscopic colorectal surgery
Patients underwent laparoscopic left colectomy, sigmoid resection or rectal surgery according to the location of tumor.

Locations

Country Name City State
China Beijing Cancer Hospital Beijing Beijing
China China-Japan Friendship Hospital Beijing Beijing
China Chinese PLA General Hospital Beijing Beijng
China Peking Union Medical College Hospital Beijing Beijing

Sponsors (5)

Lead Sponsor Collaborator
Cancer Institute and Hospital, Chinese Academy of Medical Sciences China-Japan Friendship Hospital, Chinese PLA General Hospital, Peking Union Medical College Hospital, Peking University Cancer Hospital & Institute

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Metastatic rate of No.253 lymph node Pathologically confirmed tumor cell infiltration in the No.253 lymph node About 10 days after surgery
Secondary Number of harvested lymph nodes Total number of lymph nodes dissected in the pathology report About 10 days after surgery
Secondary Incidence of postoperative complications The proportion of short-term complications occurring within 30 days post-surgery 30 days after surgery
Secondary 5-year local recurrence rate Local recurrence refers to the return of cancer in the same area where it originally developed, typically after treatment has been completed. 5 years after surgery
Secondary 5-year disease free survival rate Disease free survival refers to the length of time after primary treatment during which a patient survives without any signs or symptoms of the cancer. 5 years after surgery
Secondary 5-year overall survival rate Overall survival refers to the length of time from the primary treatment that patients are still alive. 5 years after surgery
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A